The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy ... This year’s 19th Annual New York Lung Cancers Symposium® will focus on treatment strategies in early-stage lung ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Smoking is both the leading cause of cancer and the leading cause of death from cancer. 85 percent of lung cancer cases are smoking-related. Just living with a smoker increases your chance of ...
The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...
50 – 80 years of age Have a 20 pack-year history of smoking (1 pack a day for 20 years or 2 packs a day for 10 years) Are a current smoker or have quit within the last 15 years If you meet the ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback